Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients

International Journal of Molecular Medicine

Volumn 28, Issue 6, 2011, Pages 1093-1102

  Provenzani, Alessio ^a   Notarbartolo, Monica ^b   Labbozzetta, Manuela ^b   Poma, Paola ^b   Vizzini, Giovanni ^a   Salis, Paola ^a   Caccamo, Chiara ^a   Bertani, Tullio ^a   Palazzo, Ugo ^a   Polidori, Piera ^a   Gridelli, Bruno ^a   D'Alessandro, Natale ^b  

^a MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

ABCB1; CYP3A5; Liver and kidney transplant patients; Single nucleotide polymorphisms; Tacrolimus

Indexed keywords

ALBUMIN; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; EXON; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HEMATOCRIT; HOMOZYGOSITY; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ADULT; AGED; ALLELES; BIOMARKERS, PHARMACOLOGICAL; CYTOCHROME P-450 CYP3A; DNA MUTATIONAL ANALYSIS; DRUG DOSAGE CALCULATIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITALY; KIDNEY; KIDNEY TRANSPLANTATION; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 80053592755     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.794     Document Type: Article

References (66)

1. Venkataraman R, Swaminatan A, Prasad T, et al: Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29: 404-430, 1995. (Pubitemid 26004179)
2. Ihara H, Shinkuma D, Ichikawa Y, Nojima M, Nagano S and Ikoma F: Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients-importance of trough level as a practical indicator. Int J Urol 2: 151-155, 1995.
3. Jusko WJ: Analysis of tacrolimus (FK506) in relation to therapeutic drug monitoring. Ther Drug Monit 17: 596-601, 1995.
4. Sattler M, Guengerich FP, Yun CH, Christians U and Sewing KF: Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20: 753-761, 1992.
5. Saeki T, Ueda K, Tanigawara Y, Hori R and Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268: 6077-6080, 1993. (Pubitemid 23099291)
6. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I and Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissue: Proc Natl Acad Sci USA 84: 7735-7738, 1987.
7. Hall SD, Thumel KE, Watkins PB, et al: Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27: 161-166, 1999. (Pubitemid 29072066)
8. Provenzani A, Notarbartolo M, Labbozzetta M, et al: The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann Transplant 14: 23-31, 2009.
9. Macphee I, Fredericks S, Tai T, et al: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74: 1486-1489, 2002. (Pubitemid 36014218)
10. Kuehl P, Zhang J, Lin Y, et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383-391, 2001. (Pubitemid 32268418)
11. Hustert E, Haberl M, Burk O, et al: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11: 773-779, 2001. (Pubitemid 33151512)
12. Tsuchiya N, Satoh S, Tada H, et al: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78: 1182-1187, 2004. (Pubitemid 39426437)
13. Staatz CE, Goodman LK and Tett SE: Effect of CYP3A and ABCB1 single bucleotide polymorphisms on the pharmacokinetics and pharmacodynamics inhibitors: part I. Clin Pharmacokinet 49: 141-175, 2010.
14. Anglicheau D, Verstuyft C, Laurent-Puig P, et al: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients: J Am Soc Nephrol 14: 1889-1896, 2003. (Pubitemid 36750485)
15. Wang D, Johnson AD, Papp AC, Kroetz DL and Sadée W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15: 693-704, 2005. (Pubitemid 41345321)
16. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV and Gottesman MM: A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528, 2007. (Pubitemid 46175758)
17. Fredericks S, Moreton M, Reboux S, Carter ND, Goldberg L, Holt DW and MacPhee IA: Multi-drug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 82: 705-708, 2006. (Pubitemid 44395243)
18. Von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M and Armstrong VW: No influence of the MDR-1 C3435T polymorphisms or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporine A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 47: 1048-1052, 2001. (Pubitemid 32493590)
19. Jeannesson E, Albertini L, Siest G, et al: Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundam Clin Pharmacol 21: 411-418, 2007. (Pubitemid 47084031)
20. Cascorbi I, Gerloff T, Johne A, et al: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69: 169-174, 2001. (Pubitemid 32225417)
21. Utecht KN, Hiles JJ and Kolesar J: Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am J Health Syst Pharm 63: 2340-2348, 2006. (Pubitemid 44851775)
22. Anglicheau D, Flamant M, Schlageter MH, et al: Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 18: 2409-2414, 2003. (Pubitemid 37336834)
23. Roberts PJ, Rollins KD, Kashuba AD, et al: The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. Drug Metab Dispos 36: 1465-1469, 2008.
24. Van Schaik RHN, Van der Heiden IP, Van den Anker JN and Lindemans J: CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48: 1668-1671, 2002.
25. Lamba JK, Lin YS, Shuetz EG and Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54: 1271-1294, 2002. (Pubitemid 35284253)
26. Macphee IA and Holt DW: A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. Transplantation 85: 163-165, 2008.
27. Dirks NL, Huth B, Yates CR and Meibohm B: Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther 42: 701-718, 2004. (Pubitemid 39625130)
28. Ifergan I, Bernard NF, Bruneau J, Alary M, Tsoukas CM and Roger M: Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians. AIDS 16: 2340-2342, 2002. (Pubitemid 35449023)
29. Cavaco I, Gil JP, Gil-Berglund E and Ribeiro V: CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab 41: 1345-1350, 2003. (Pubitemid 37266126)
30. Kim RB, Leake BF, Choo EF, et al: Identification of functionally variant MDR1 alleles among Europeans Americans and Africans Americans. Clin Pharmacol Ther 70: 189-199, 2001. (Pubitemid 32777772)
31. Allabi AC, Horsmans Y, Bouchra I and Gala JL: Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype in a West Black African population. Eur J Clin Pharmacol 61: 97-102, 2005. (Pubitemid 40674741)
32. Tang K, Wong LP, Lee EJ, Chong SS and Lee CG: Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet 13: 783-797, 2004. (Pubitemid 38515208)
33. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS and Lee CG: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12: 437-450, 2007. (Pubitemid 34913526)
34. Fromm MF: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 54: 1295-1310, 2002.
35. Pauli-Magnus C and Kroetz DL: Functional implications of genetic polymoprhisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 21: 904-913, 2004.
36. Ameyaw MM, Regateiro F, Li T, et al: MDR1 pharmacogenetics of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11: 217-221, 2001. (Pubitemid 32319871)
37. Wang J, Zeevi A, McCurry K, et al: Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5*3/ *3 non-expressors. Transpl Immunol 15: 235-240, 2006. (Pubitemid 43129392)
38. Kroetz DL, Pauli-Magnus C, Hodges LM, et al: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13: 481-494, 2003. (Pubitemid 37034590)
39. Wang H, Ding K, Zhang Y, Jin L, Kullo IJ and He F: Comparative and evolutionary pharmacogenetics of ABCB1: complex signatures of positive selection on coding and regulatory regions. Pharmacogenet Genomics 17: 667-678, 2007. (Pubitemid 47057716)
40. Day Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD and Thummel KE: Effects of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34: 836-847, 2007.
41. Li D, Lu W, Zhu JY, Gao J, Lou YQ and Zhang GL: Population pharmacokinetic of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther 32: 505-515, 2007. (Pubitemid 47404287)
42. Kalow W, Tang BK and Endrenyi L: Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8: 283-289, 1998. (Pubitemid 28372321)
43. Goto M, Masuda S, Kiuchi T, et al: CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14: 471-478, 2004. (Pubitemid 38971237)
44. MacPhee IA, Fredericks S, Tai T, et al: The influence of pharmacogenetics on the time to achieve target tacrolimus concentration after kidney transplantation. Am J Transplant 4: 914-919, 2004. (Pubitemid 38745590)
45. Thervet E, Anglicheau D, King B, et al: Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to dose ratio in renal transplant recipients. Transplantation 76: 1233-1235, 2003. (Pubitemid 37339651)
46. Haufroid V, Mourad M, Van Kerckhove V, et al: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14: 147-154, 2004. (Pubitemid 38373108)
47. Roy JN, Barama A, Poirier C, Vinet B and Roger M: CYP3A4, CYP3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 16: 659-665, 2006. (Pubitemid 44223077)
48. Zheng H, Webber S, Zeevi A, et al: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3: 477-483, 2003. (Pubitemid 36560101)
49. Zheng H, Zeevi A, Schuetz E, et al: Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 44: 135-140, 2004. (Pubitemid 38114311)
50. Wei-lin W, Jing J, Shu-sen Z, Li-hua W, Ting-bo L, Song-feng Y and Sheng Y: Tacrolimus dose requirements in relation to donor and recipients ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 12: 775-780, 2006.
51. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y and Inui K: Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 16: 119-127, 2006. (Pubitemid 43145680)
52. Li D, Zhu JY, Gao J, Wang X, Lou YQ and Zhang GL: Polymorphisms of tumor necrosis factor-α, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clin Chim Acta 383: 133-139, 2007. (Pubitemid 47016461)
53. Fukudo M, Yano I, Yoshimura A, et al: Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimusrelated renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 18: 413-423, 2008. (Pubitemid 351535942)
54. Hitzl M, Drescher S, Van der Kuip H, et al: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11: 293-298, 2001. (Pubitemid 32537402)
55. Goto M, Masuda S and Saito H: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12: 451-457, 2002. (Pubitemid 34913527)
56. Sakaeda T, Nakamura T and Okumura K: Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodinamics of drugs. Pharmacogenetics 4: 397-410, 2003. (Pubitemid 36857176)
57. Hoffmeyer S, Burk O, Von Richter O, et al: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478, 2000. (Pubitemid 30183327)
58. Cheung CY, Op den Buijsch RA, Wong KM, et al: Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Pharmacogenomics 7: 563-574, 2006.
59. Undre NA and Möller A: Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group. Transpl Int 7 (Suppl 1): S15-S21, 1994.
60. Hu RH, Lee PH and Tsai MK: Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. Transplant Proc 32: 1689-1692, 2000.
61. May DG, Porter J, Wilkinson GR and Branch RA: Frequency distribution of dapsone-N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharm Ther 55: 492-500, 1994. (Pubitemid 24192235)
62. Machado CG, Calado RT, Garcia AB and Falcão RP: Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T-lymphocytes. Braz J Med Biol Res 36: 1653-1657, 2003.
63. Brenner SS and Klotz U: P-glycoprotein function in the elderly. Eur J Clin Pharmacol 60: 97-102, 2004. (Pubitemid 38626438)
64. Yamauchi A, Ieiri I, Kataoka Y, et al: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74: 571-572, 2002.
65. Zahir H, McLachlan AJ, Nelson A, McCaughan G, Gleeson M and Akhlaghi F: Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit 27: 422-430, 2005. (Pubitemid 41098815)
66. Lee JY, Hahn HJ, Son IJ, Suh KS, Yi NJ, Oh JM and Shin WG: Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. Pharmacotherapy 26: 1069-1077, 2006. (Pubitemid 44167815)